{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:03:42Z","timestamp":1772809422732,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["213"],"award-info":[{"award-number":["213"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treosulfan is increasingly used as myeloablative agent in conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT). In our pediatric HSCT program, myalgia was regularly observed after treosulfan-based conditioning, which is a relatively unknown side effect. Using a natural language processing and text-mining tool (CDC), we investigated whether treosulfan compared with busulfan was associated with an increased risk of myalgia. Furthermore, among treosulfan users, we studied the characteristics of given treatment of myalgia, and studied prognostic factors for developing myalgia during treosulfan use. Electronic Health Records (EHRs) until 28\u00a0days after HSCT were screened using the CDC for myalgia and 22 synonyms. Time to myalgia, location of pain, duration, severity and drug treatment were collected. Pain severity was classified according to the WHO pain relief ladder. Logistic regression was performed to assess prognostic factors. 114 patients received treosulfan and 92 busulfan. Myalgia was reported in 37 patients; 34 patients in the treosulfan group and 3 patients in the busulfan group (p\u2009=\u20090.01). In the treosulfan group, median time to myalgia was 7\u00a0days (0\u201312) and median duration of pain was 19\u00a0days (4\u201373). 44% of patients needed strong acting opiates and adjuvant medicines (e.g. ketamine). Hemoglobinopathy was a significant risk factor, as compared to other underlying diseases (OR 7.16 95% CI 2.09\u201330.03, p\u2009=\u20090.003). Myalgia appears to be a common adverse effect of treosulfan in pediatric HSCT, especially in hemoglobinopathy. Using the CDC, EHRs were easily screened to detect this previously unknown side effect, proving the effectiveness of the tool. Recognition of treosulfan-induced myalgia is important for adequate pain management strategies and thereby for improving the quality of hospital stay.<\/jats:p>","DOI":"10.1038\/s41598-021-98669-3","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:20:00Z","timestamp":1632738000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool"],"prefix":"10.1038","volume":"11","author":[{"given":"M. Y. Eileen C.","family":"van der Stoep","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Berghuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbert G. M.","family":"Bredius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie P.","family":"Buddingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander B.","family":"Mohseny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans J. W.","family":"Smiers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan C.","family":"Lankester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Zwaveling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"4","key":"98669_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1471-0528.1977.tb12581.x","volume":"84","author":"J Fennelly","year":"1977","unstructured":"Fennelly, J. Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma. Br. J. Obstet. Gynaecol. 84(4), 300\u2013303 (1977).","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"7","key":"98669_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1471-0528.1985.tb01462.x","volume":"92","author":"ID Duncan","year":"1985","unstructured":"Duncan, I. D. & Clayton, L. A. Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan\u2014a phase II study. Br. J. Obstet. Gynaecol. 92(7), 762\u2013767 (1985).","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"4","key":"98669_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1471-0528.1990.tb01813.x","volume":"97","author":"J Masding","year":"1990","unstructured":"Masding, J. et al. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br. J. Obstet. Gynaecol. 97(4), 342\u2013351 (1990).","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"1","key":"98669_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1006\/gyno.1998.5103","volume":"71","author":"M Gropp","year":"1998","unstructured":"Gropp, M., Meier, W. & Hepp, H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol. Oncol. 71(1), 94\u201398 (1998).","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"98669_CR5","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen, D. W. et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): A randomised, non-inferiority, phase 3 trial. Lancet Haematol. 7(1), e28\u2013e39 (2020).","journal-title":"Lancet Haematol."},{"issue":"2","key":"98669_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2012-04-423822","volume":"120","author":"ME Bernardo","year":"2012","unstructured":"Bernardo, M. E. et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: Results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 120(2), 473\u2013476 (2012).","journal-title":"Blood"},{"issue":"2","key":"98669_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00277-014-2196-8","volume":"94","author":"H Boztug","year":"2015","unstructured":"Boztug, H. et al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann. Hematol. 94(2), 297\u2013306 (2015).","journal-title":"Ann. Hematol."},{"issue":"12","key":"98669_CR8","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","volume":"20","author":"LM Burroughs","year":"2014","unstructured":"Burroughs, L. M. et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: A prospective multicenter trial. Biol. Blood Marrow Transplant. 20(12), 1996\u20132003 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"98669_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3324\/haematol.2013.094730","volume":"99","author":"K Lehmberg","year":"2014","unstructured":"Lehmberg, K. et al. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. Haematologica 99(1), 180\u2013184 (2014).","journal-title":"Haematologica"},{"issue":"4","key":"98669_CR10","doi-asserted-by":"publisher","first-page":"e61637","DOI":"10.1371\/journal.pone.0061637","volume":"8","author":"V Mathews","year":"2013","unstructured":"Mathews, V. et al. Improved clinical outcomes of high risk beta thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS ONE 8(4), e61637 (2013).","journal-title":"PLoS ONE"},{"issue":"3","key":"98669_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","volume":"128","author":"B Morillo-Gutierrez","year":"2016","unstructured":"Morillo-Gutierrez, B. et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: A multicenter experience. Blood 128(3), 440\u2013448 (2016).","journal-title":"Blood"},{"issue":"12","key":"98669_CR12","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/bmt.2010.343","volume":"46","author":"J Wachowiak","year":"2011","unstructured":"Wachowiak, J. et al. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: A retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 46(12), 1510\u20131518 (2011).","journal-title":"Bone Marrow Transplant."},{"key":"98669_CR13","unstructured":"Medac Gesellschaft f\u00fcr klinische Spezialpr\u00e4parate mbH. Treosulfan (treosulfan) [Summary of Product Characteristics]. European Medicines Agency. URL: https:\/\/www.medicines.org.uk\/emc\/product\/1414\/smpc Revised December 2016. Accessed January 2020."},{"key":"98669_CR14","unstructured":"Medac Gesellschaft f\u00fcr klinische Spezialpr\u00e4parate mbH. Trecondi (treosulfan) [Summary of Product Characteristics]. European Medicines Agency. URL: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trecondi-epar-product-information_en.pdf. Published July 2019. Accessed January 2020."},{"key":"98669_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","volume":"37","author":"JA Casey","year":"2016","unstructured":"Casey, J. A., Schwartz, B. S., Stewart, W. F. & Adler, N. E. Using electronic health records for population health research: A review of methods and applications. Annu. Rev. Public Health. 37, 61\u201381 (2016).","journal-title":"Annu. Rev. Public Health."},{"key":"98669_CR16","first-page":"2","volume":"2","author":"SA van Laar","year":"2020","unstructured":"van Laar, S. A., Gombert-Handoko, K. B., Guchelaar, H. J. & Zwaveling, J. An electronic health record text mining tool to collect real-world drug treatment outcomes: A validation study in patients with metastatic renal cell carcinoma. Clin. Pharmacol. Ther. 2, 2 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"98669_CR17","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s00520-018-4161-x","volume":"26","author":"R Fernandes","year":"2018","unstructured":"Fernandes, R. et al. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: A prospective multi-center study. Support Care Cancer. 26(9), 3073\u20133081 (2018).","journal-title":"Support Care Cancer."},{"issue":"1b","key":"98669_CR18","first-page":"523","volume":"25","author":"AS Ardavanis","year":"2005","unstructured":"Ardavanis, A. S., Ioannidis, G. N. & Rigatos, G. A. Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res. 25(1b), 523\u2013525 (2005).","journal-title":"Anticancer Res."},{"issue":"1","key":"98669_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1212\/WNL.47.1.115","volume":"47","author":"RJ Freilich","year":"1996","unstructured":"Freilich, R. J., Balmaceda, C., Seidman, A. D., Rubin, M. & DeAngelis, L. M. Motor neuropathy due to docetaxel and paclitaxel. Neurology 47(1), 115\u2013118 (1996).","journal-title":"Neurology"},{"issue":"6","key":"98669_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1445-5994.2005.00846.x","volume":"35","author":"BG Hughes","year":"2005","unstructured":"Hughes, B. G. & Stuart-Harris, R. Docetaxel-induced myositis: Report of a novel side-effect. Int. Med. J. 35(6), 369\u2013370 (2005).","journal-title":"Int. Med. J."},{"issue":"1","key":"98669_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/ijd.12437","volume":"55","author":"RR Winkelmann","year":"2016","unstructured":"Winkelmann, R. R. et al. Paclitaxel-induced diffuse cutaneous sclerosis: A case with associated esophageal dysmotility, Raynaud\u2019s phenomenon, and myositis. Int. J. Dermatol. 55(1), 97\u2013100 (2016).","journal-title":"Int. J. Dermatol."},{"key":"98669_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ejps.2017.09.011","volume":"109","author":"M Romanski","year":"2017","unstructured":"Romanski, M., Kasprzyk, A., Walczak, M., Ziolkowska, A. & Glowka, F. Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevance. Eur. J. Pharm. Sci. 109, 616\u2013623 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"98669_CR23","unstructured":"Pierre Fabre M\u00e9dicament . Busilvex (busulfan) [Summary of Product Characteristics]. European Medicines Agency. URL: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/busilvex-epar-product-information_en.pdf Revised August 2017. Accessed January 2020."},{"issue":"5","key":"98669_CR24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14960","volume":"179","author":"M van der Stoep","year":"2017","unstructured":"van der Stoep, M. et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: A prospective multicentre study. Br. J. Haematol. 179(5), 772\u2013780 (2017).","journal-title":"Br. J. Haematol."},{"issue":"7","key":"98669_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","volume":"137","author":"PS Phillips","year":"2002","unstructured":"Phillips, P. S. et al. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137(7), 581\u2013585 (2002).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"98669_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bjh.15011","volume":"180","author":"A Wonkam","year":"2018","unstructured":"Wonkam, A. et al. Clinical and genetic factors are associated with pain and hospitalisation rates in sickle cell anaemia in Cameroon. Br. J. Haematol. 180(1), 134\u2013146 (2018).","journal-title":"Br. J. Haematol."},{"issue":"3","key":"98669_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/cpt.1966","volume":"108","author":"SA van Laar","year":"2020","unstructured":"van Laar, S. A., Gombert-Handoko, K. B., Guchelaar, H. J. & Zwaveling, J. An electronic health record text mining tool to collect real-world drug treatment outcomes: A validation study in patients with metastatic renal cell carcinoma. Clin. Pharmacol. Ther. 108(3), 644\u2013652 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"98669_CR28","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","volume":"129","author":"E Gluckman","year":"2017","unstructured":"Gluckman, E. et al. Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 129(11), 1548\u20131556 (2017).","journal-title":"Blood"},{"issue":"6","key":"98669_CR29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood-2013-03-489112","volume":"122","author":"F Locatelli","year":"2013","unstructured":"Locatelli, F. et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 122(6), 1072\u20131078 (2013).","journal-title":"Blood"},{"key":"98669_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjdrc-2020-002018","volume":"9","author":"A van der Vaart","year":"2021","unstructured":"van der Vaart, A. et al. Incidence and determinants of hypophosphatemia in diabetic ketoacidosis: an observational study. BMJ Open Diabetes Res. Care. 9, 1 (2021).","journal-title":"BMJ Open Diabetes Res. Care."},{"key":"98669_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14831","author":"SA van Laar","year":"2021","unstructured":"van Laar, S. A., de Boer, M. G. J., Gombert-Handoko, K. B., Guchelaar, H. J. & Zwaveling, J. Liver and kidney function in patients with Covid-19 treated with remdesivir. Br. J. Clin. Pharmacol. https:\/\/doi.org\/10.1111\/bcp.14831 (2021).","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98669-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98669-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98669-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:07:27Z","timestamp":1670083647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98669-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98669"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98669-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19084"}}